Compass Therapeutics, Inc. (CMPX) Discusses Positive Secondary Endpoint Results From COMPANION-002 Study in Advanced Biliary Tract Cancer Transcript

Verdict

Headline takes no side. We score CMPX +0.80 — strongly bullish.

Headline says

No call

No rating or direction in the headline

Expected · CMPX

+0.80strongly bullish

−1 bearish0bullish +1

More positive than 90% of ticker scores this week